Team NeoPhen, in collaboration with team NeuroDev (Dr. Andrée Delahaye), receive support from the CCHS Foundation in 2022 to study the genetic dysregulations that could be associated with Congenital Central Hypoventilation Syndrome (CCHS).
Members of the NeoPhen and NeuroDev teams involved in the project
From left to right: Dr. Jorge Gallego, Eleonore Sizun, Dr. Nelina Ramanantsoa, Maud Ringot, Dr. Andrée Delahaye, Boris Matrot, Pr. Stéphane Dauger and Thomas Bourgeois.
We propose to analyse the respiratory function in mice carrying the PHOX2B +7Ala mutation which reproduces the main symptoms of CCHS: apneas, hypoventilation and lack of ventilatory response to CO2. This mouse model has shown that the PHOX2B +7Ala mutation causes gene deregulations in two brainstem regions involved in respiratory control. The team hopes to identify pharmacological treatments capable of regulating gene expression and possibly improving the respiratory function of the animals.
Sleep2Develop research program
The Sleep2Develop program investigates the role of sleep as a promotor of neurodevelopment and identifies the sleep determinants of childhood development. This is rephrased as Sleep(to)Develop? or Sleep(to)Develop! Our sleep research combines clinical and...
NemoClinics platform is hiring an engineer. Check out the opportunity here: U 1141 -Ingénieur-e en expérimentation et instrumentation biologiques- CDD 2023 Read more
Research program on CCHS
CCHS is a disease characterized by a congenital impairment of the central control of breathing, associated with dysfunctions of the autonomic nervous system (ANS) (Gallego, 2012). At birth, patients have severe and persistent hypoventilation during sleep and a...
Breaking news for Central Congenital Hypoventilation Syndrome
In collaboration with Dr. Muriel Thoby-Brisson (Université de Bordeaux, Institut de Neurosciences Cognitives et Intégratives d’Aquitaine, CNRS), and thanks to Fondation Air Liquide, Association Française du syndrome d'Ondine and start-up company ATMOSR, team NeoPhen...